Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient

See also
Status	Clinical Trial	Phase
Completed	`NCT02229851` - Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.	Phase 3
Completed	`NCT01563926` - Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency	Phase 3
Completed	`NCT01562834` - Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients	Phase 4
Completed	`NCT01109017` - Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency	N/A
Completed	`NCT01706783` - A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency	Phase 1
Completed	`NCT01245374` - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents	Phase 4
Completed	`NCT00184730` - Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)	Phase 3
Completed	`NCT01502124` - Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency	Phase 3
Completed	`NCT00519558` - Growth Hormone Deficiency in Adults (GHDA)	Phase 3
Completed	`NCT01604161` - Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome	N/A
Terminated	`NCT01698944` - Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency	Phase 4
Completed	`NCT03075644` - A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency	Phase 3
Recruiting	`NCT02616562` - Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency	Phase 2
Completed	`NCT02005198` - Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)	N/A
Completed	`NCT00567385` - Liquid Somatropin Formulation in Children With Growth Hormone Deficiency	Phase 4
Completed	`NCT01009905` - An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)	N/A
Completed	`NCT03186495` - Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function	Phase 1
Completed	`NCT00934063` - An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®	N/A
Completed	`NCT00715689` - Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083	Phase 2
Completed	`NCT00722540` - Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083	Phase 1

NCT number	NCT00102817
Study type	Interventional
Source	Novo Nordisk A/S
Contact
Status	Completed
Phase	Phase 3
Start date	May 2003
Completion date	December 2006

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms